02.12.2020
AiCuris receives approval from BfArM to initiate Compassionate Use Program for Pritelivir in Germany
Approval from the German “Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)” to initiate a Compassionate Use Program (Härtefallprogramm) for pritelivir.
more ...
02.12.2020
Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente
„Wir können lebenswichtige Medikamente zur Behandlung von COVID-19-Patienten zur Verfügung stellen, aber wir benötigen signifikante Unterstützung bei der Finanzierung der Entwicklungs- und Produktionskosten – jetzt!“
more ...
17.08.2020
AiCuris launches “PREP – Pandemic and Resistance Emergency Preparedness” program at upcoming 4th AMR Conference
AiCuris has launched a four-pillar program, “PREP – Pandemic and Resistance Emergency Preparedness”
more ...
09.06.2020
Royalty Pharma Acquires Partial Royalty Interest on Prevymis™ (Letermovir) from AiCuris
Royalty Pharma and AiCuris have entered into an agreement whereby Royalty Pharma has acquired a partial royalty interest on Prevymis™ (letermovir) from AiCuris for a one-time-payment of $220 million.
more ...
05.06.2020
AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients
AiCuris has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for oral pritelivir, AiCuris’ lead candidate for the treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV)
more ...
02.04.2020
AiCuris gets involved in the fight against Corona
“In times like these, biotech and pharmaceutical companies have a great societal responsibility”
more ...
12.02.2020
AiCuris collaborates with myTomorrows to initiate an Early Access Program for Pritelivir
AiCuris and myTomorrows today announced a collaboration to develop an Early Access Program (EAP) for pritelivir, currently undergoing Phase II testing for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
more ...